PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för acalabrutinib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

31 hits

Bibliografisk träff 2021-09-01

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.

Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ.

Haematologica · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.3324/haematol.2020.272500

Bibliografisk träff 2021-05-07

Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.

Izutsu K, Ando K, Ennishi D, Shibayama H, Suzumiya J, Yamamoto K, Ichikawa S, Kato K, Kumagai K, Patel P, Iizumi S, Hayashi N, Kawasumi H, Murayama K, Nagai H.

Cancer Sci · research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1111/cas.14886

Bibliografisk träff 2021-02-11

Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.

Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML.

Am J Hematol · letter · DOI 10.1002/ajh.26109

Bibliografisk träff 2021-02-10

EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.

Delgado J, Josephson F, Camarero J, Garcia-Ochoa B, Lopez-Anglada L, Prieto-Fernandez C, van Hennik PB, Papadouli I, Gisselbrecht C, Enzmann H, Pignatti F.

Oncologist · review-article; review; journal article · DOI 10.1002/onco.13685

Bibliografisk träff 2021-02-05

The role of acalabrutinib in adults with chronic lymphocytic leukemia.

Fakhri B, Andreadis C.

Ther Adv Hematol · review-article; review; journal article · DOI 10.1177/2040620721990553

Bibliografisk träff 2021-02-01

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.

Estupiñán HY, Wang Q, Berglöf A, Schaafsma GCP, Shi Y, Zhou L, Mohammad DK, Mohammad DK, Yu L, Vihinen M, Zain R, Smith CIE.

Leukemia · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41375-021-01123-6

Bibliografisk träff 2021-01-13

Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.

Benner B, Carson WE.

J Hematol Oncol · letter; research support, n.i.h., extramural · DOI 10.1186/s13045-020-00999-8

Bibliografisk träff 2021-01-11

Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.

Ghia P, Dlugosz-Danecka M, Scarfò L, Jurczak W.

Leuk Lymphoma · journal article · DOI 10.1080/10428194.2020.1864352

Bibliografisk träff 2020-12-11

Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3.

Morell A, Čermáková L, Novotná E, Laštovičková L, Haddad M, Haddad A, Portillo R, Wsól V.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers12123731

Bibliografisk träff 2020-11-20

Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.

Danilov AV, Persky DO.

Br J Haematol · comparative study; review; journal article · DOI 10.1111/bjh.17184

Bibliografisk träff 2020-10-06

Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.

Davids MS, Waweru C, Le Nouveau P, Padhiar A, Singh G, Abhyankar S, Leblond V.

Clin Ther · comparative study; research support, non-u.s. gov't; systematic review; network meta-analysis; journal article · DOI 10.1016/j.clinthera.2020.08.017

Bibliografisk träff 2020-08-05

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.

Zhang T, Harrison MR, O'Donnell PH, Alva AS, Hahn NM, Appleman LJ, Cetnar J, Burke JM, Fleming MT, Milowsky MI, Mortazavi A, Shore N, Sonpavde GP, Schmidt EV, Bitman B, Munugalavadla V, Izumi R, Patel P, Staats J, Chan C, Weinhold KJ, George DJ.

Cancer · clinical trial, phase ii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1002/cncr.33067

Bibliografisk träff 2020-08-01

Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma.

Badillo M, Nava D, Rosa M, Chen W, Guerrero M, Wang M.

Clin J Oncol Nurs · journal article · DOI 10.1188/20.cjon.392-398

Bibliografisk träff 2020-07-01

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.

Sun C, Nierman P, Kendall EK, Cheung J, Gulrajani M, Herman SEM, Pleyer C, Ahn IE, Stetler-Stevenson M, Yuan CM, Maric I, Gaglione EM, Harris HM, Pittaluga S, Wang MH, Patel P, Farooqui MZH, Izumi R, Hamdy A, Covey T, Wiestner A.

Blood · clinical trial, phase ii; research support, n.i.h., intramural; comparative study; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1182/blood.2019003715

Bibliografisk träff 2020-07-01

Acalabrutinib - a new option in CLL.

Romero D.

Nat Rev Clin Oncol · comment; journal article · DOI 10.1038/s41571-020-0381-3

Bibliografisk träff 2020-04-24

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia.

Författaruppgift saknas

Aust Prescr · review-article; review; journal article · DOI 10.18773/austprescr.2020.027

Bibliografisk träff 2020-04-01

Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia.

Davids MS.

Lancet · comment; journal article · DOI 10.1016/s0140-6736(20)30372-x

Bibliografisk träff 2020-03-19

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.

Isaac K, Mato AR.

Cancer Manag Res · review-article; review; journal article · DOI 10.2147/cmar.s219570

Bibliografisk träff 2020-01-08

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.

Woyach JA, Blachly JS, Rogers KA, Bhat SA, Jianfar M, Lozanski G, Weiss DM, Andersen BL, Gulrajani M, Frigault MM, Hamdy A, Izumi R, Munugalavadla V, Quah C, Wang MH, Byrd JC.

Cancer Discov · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1158/2159-8290.cd-19-1130

Bibliografisk träff 2019-12-19

Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia.

Buske C.

Lancet Haematol · letter · DOI 10.1016/s2352-3026(19)30214-5

Bibliografisk träff 2019-11-18

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.

Morabito F, Recchia AG, Vigna E, Botta C, Skafi M, Abu-Rayyan M, Atrash M, Galimberti S, Morabito L, Al-Janazreh H, Martino M, Cutrona G, Gentile M.

Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2019.1689959

Bibliografisk träff 2019-09-30

Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.

Girard J, Reneau J, Devata S, Wilcox RA, Kaminski MS, Mercer J, Carty S, Phillips TJ.

Onco Targets Ther · research-article; journal article · DOI 10.2147/ott.s155778

Bibliografisk träff 2019-07-29

Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.

Spriano F, Tarantelli C, Gaudio E, Gerlach MM, Priebe V, Cascione L, Bernasconi E, Targa A, Mascia M, Dirnhofer S, Stathis A, Zucca E, Bertoni F.

Br J Haematol · research support, non-u.s. gov't; journal article · DOI 10.1111/bjh.16118

Bibliografisk träff 2019-07-12

Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.

Pepin XJH, Moir AJ, Mann JC, Sanderson NJ, Barker R, Meehan E, Plumb AP, Bailey GR, Murphy DS, Krejsa CM, Andrew MA, Ingallinera TG, Slatter JG.

Eur J Pharm Biopharm · journal article · DOI 10.1016/j.ejpb.2019.07.011

Bibliografisk träff 2019-04-09

Acalabrutinib for mantle cell lymphoma.

Witzig TE, Inwards D.

Blood · research support, non-u.s. gov't; review; journal article · DOI 10.1182/blood.2019852368

Bibliografisk träff 2019-01-18

Novel BTK inhibitor acalabrutinib (ACP-196) tightly binds to site I of the human serum albumin as observed by spectroscopic and computational studies.

Abdelhameed AS, Alanazi AM, Bakheit AH, Hassan ES, Herqash RN, Almutairi FM.

Int J Biol Macromol · journal article · DOI 10.1016/j.ijbiomac.2019.01.083

Bibliografisk träff 2018-11-05

In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.

Författaruppgift saknas

Med Lett Drugs Ther · journal article

Bibliografisk träff 2017-09-07

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.

Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S, Krantz F, Pearson PG, Ulrich R, Kaptein A.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.117.242909

Bibliografisk träff 2017-06-22

The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable <i>in vitro</i> activity against chronic lymphocytic leukemia B cells with CD20 antibodies.

Golay J, Ubiali G, Introna M.

Haematologica · letter; research support, non-u.s. gov't · DOI 10.3324/haematol.2017.169334

Bibliografisk träff 2016-03-09

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.

Wu J, Zhang M, Liu D.

J Hematol Oncol · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1186/s13045-016-0250-9